Equities researchers at Piper Jaffray Companies started coverage on shares of Teleflex (NYSE:TFX) in a research note issued on Friday, November 10th, MarketBeat Ratings reports. The firm set an “overweight” rating and a $295.00 price target on the medical technology company’s stock. Piper Jaffray Companies’ target price suggests a potential upside of 11.57% from the company’s previous close.
A number of other analysts have also weighed in on TFX. BidaskClub lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Jefferies Group restated a “buy” rating and set a $230.00 price target on shares of Teleflex in a research report on Thursday, August 3rd. Needham & Company LLC restated a “buy” rating on shares of Teleflex in a research report on Friday, August 4th. Deutsche Bank restated a “buy” rating and set a $238.00 price target (up previously from $220.00) on shares of Teleflex in a research report on Wednesday, August 9th. Finally, Zacks Investment Research downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company’s stock. Teleflex currently has an average rating of “Hold” and a consensus target price of $274.44.
Shares of Teleflex (NYSE:TFX) traded down $5.78 during trading on Friday, reaching $264.41. 296,300 shares of the company’s stock were exchanged, compared to its average volume of 259,939. The company has a debt-to-equity ratio of 0.88, a current ratio of 4.72 and a quick ratio of 3.70. Teleflex has a twelve month low of $142.97 and a twelve month high of $271.23. The firm has a market cap of $12,170.00, a price-to-earnings ratio of 33.09, a price-to-earnings-growth ratio of 2.29 and a beta of 1.05.
In other news, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $237.18, for a total value of $47,436.00. Following the transaction, the director now directly owns 8,080 shares of the company’s stock, valued at $1,916,414.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders sold 600 shares of company stock worth $138,162. Insiders own 2.39% of the company’s stock.
Several large investors have recently bought and sold shares of TFX. Teachers Advisors LLC lifted its stake in shares of Teleflex by 4.3% in the first quarter. Teachers Advisors LLC now owns 47,518 shares of the medical technology company’s stock worth $9,206,000 after buying an additional 1,958 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its stake in Teleflex by 10.0% during the first quarter. Nomura Asset Management Co. Ltd. now owns 5,500 shares of the medical technology company’s stock worth $1,066,000 after purchasing an additional 500 shares during the period. Xact Kapitalforvaltning AB raised its stake in Teleflex by 2.7% during the second quarter. Xact Kapitalforvaltning AB now owns 3,482 shares of the medical technology company’s stock worth $723,000 after purchasing an additional 90 shares during the period. Pennsylvania Trust Co raised its stake in Teleflex by 50.8% during the second quarter. Pennsylvania Trust Co now owns 3,265 shares of the medical technology company’s stock worth $678,000 after purchasing an additional 1,100 shares during the period. Finally, Creative Planning raised its stake in Teleflex by 69.5% during the second quarter. Creative Planning now owns 3,828 shares of the medical technology company’s stock worth $795,000 after purchasing an additional 1,569 shares during the period. 89.26% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was posted by BBNS and is the sole property of of BBNS. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/markets/piper-jaffray-companies-begins-coverage-on-teleflex-incorporated-tfx/1774630.html.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with our FREE daily email newsletter.